Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) EBT (2020 - 2025)

Historic EBT for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$12.7 million.

  • Tarsus Pharmaceuticals' EBT rose 4599.99% to -$12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.0 million, marking a year-over-year increase of 3899.41%. This contributed to the annual value of -$115.6 million for FY2024, which is 1496.69% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' EBT stood at -$12.7 million, which was up 4599.99% from -$20.2 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' EBT registered a high of $10.7 million during Q1 2021, and its lowest value of -$42.5 million during Q4 2023.
  • For the 5-year period, Tarsus Pharmaceuticals' EBT averaged around -$20.1 million, with its median value being -$22.5 million (2022).
  • In the last 5 years, Tarsus Pharmaceuticals' EBT soared by 64793.05% in 2021 and then plummeted by 47411.81% in 2023.
  • Tarsus Pharmaceuticals' EBT (Quarter) stood at -$14.4 million in 2021, then rose by 5.61% to -$13.6 million in 2022, then plummeted by 211.62% to -$42.5 million in 2023, then skyrocketed by 45.63% to -$23.1 million in 2024, then skyrocketed by 45.06% to -$12.7 million in 2025.
  • Its last three reported values are -$12.7 million in Q3 2025, -$20.2 million for Q2 2025, and -$25.0 million during Q1 2025.